--- title: Webinar_MabsDisco_June_2025 --- ![logo_blanc-300](https://go.proteogenix.science/hs-fs/hubfs/logo_blanc-300.png?width=300&height=179&name=logo_blanc-300.png) # **Bridging Artificial Intelligence and Wet Lab: a new era in Antibody Development** ## **Webinar on demand** Monoclonal antibody-based therapies are expanding fast, driven by their tremendous therapeutic potential. In parallel, artificial intelligence is redefining the way antibodies are discovered and optimized—especially for complex targets such as Multi-Pass Membrane Proteins. When combined with wet lab expertise, AI plays a crucial role across all stages of development. ### Replay Webinar Form # Your Speaker ![karim MEF](https://go.proteogenix.science/hubfs/karim%20MEF.png "karim MEF") Karim SEBANE, Ph.D., MBA Account Manager I Monoclonal Antibodies ![logo_bleu-300-1](https://go.proteogenix.science/hubfs/logo_bleu-300-1.jpg "logo_bleu-300-1") --- --- --- # What will you learn ? - The role of monoclonal antibodies and their main therapeutic applications - Key strategies to tackle complex targets, including Multi-Pass Membrane Proteins - How AI  is transforming antibody discovery, from screening to optimization - Why wet lab expertise remains indispensable in the AI era - Why the future is now: designing de novo antibodies directly in silico Monoclonal antibody-based therapies are expanding fast, driven by their tremendous therapeutic potential. In parallel, artificial intelligence is redefining the way antibodies are discovered and optimized—especially for complex targets such as Multi-Pass Membrane Proteins. When combined with wet lab expertise, AI plays a crucial role across all stages of development. What will you'll learn ?  [![ft_logo](https://go.proteogenix.science/hubfs/ft_logo.svg)](https://www.proteogenix.science/) © 2026 ProteoGenix | All rights reserved | [Legal notices](https://www.proteogenix.science/legal-notices/)